Overview

ADVANCED Phase II Trial of Weekly vs 3 Weekly Docetaxel and Cisplatin Followed by Gemcitabine in Non-small-cell Lung Cancer (NSCLC)

Status:
Completed

Trial end date:
2008-08-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label, randomized phase II trial whose aim is to assess the antitumor activity of two sequential schedules of docetaxel and cisplatin followed by gemcitabine.

Phase:

Phase 2

Details

Lead Sponsor:

Sanofi

Treatments:

Cisplatin
Docetaxel
Gemcitabine